Item 1. Financial Statements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Operations
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
(millions, except per share data) (unaudited)
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Sales
|
$
|
16,169
|
|
|
$
|
17,427
|
|
|
$
|
32,364
|
|
|
$
|
34,546
|
|
Cost of sales
|
11,102
|
|
|
12,051
|
|
|
22,286
|
|
|
23,962
|
|
Gross margin
|
5,067
|
|
|
5,376
|
|
|
10,078
|
|
|
10,584
|
|
Selling, general and administrative expenses
|
3,249
|
|
|
3,495
|
|
|
6,402
|
|
|
7,009
|
|
Depreciation and amortization
|
570
|
|
|
551
|
|
|
1,116
|
|
|
1,090
|
|
Earnings from continuing operations before interest expense and income taxes
|
1,248
|
|
|
1,330
|
|
|
2,560
|
|
|
2,485
|
|
Net interest expense
|
307
|
|
|
148
|
|
|
722
|
|
|
305
|
|
Earnings from continuing operations before income taxes
|
941
|
|
|
1,182
|
|
|
1,838
|
|
|
2,180
|
|
Provision for income taxes
|
316
|
|
|
409
|
|
|
599
|
|
|
756
|
|
Net earnings from continuing operations
|
625
|
|
|
773
|
|
|
1,239
|
|
|
1,424
|
|
Discontinued operations, net of tax
|
55
|
|
|
(20
|
)
|
|
73
|
|
|
(36
|
)
|
Net earnings
|
$
|
680
|
|
|
$
|
753
|
|
|
$
|
1,312
|
|
|
$
|
1,388
|
|
Basic earnings
/
(loss) per share
|
|
|
|
|
|
|
|
Continuing operations
|
$
|
1.07
|
|
|
$
|
1.21
|
|
|
$
|
2.10
|
|
|
$
|
2.23
|
|
Discontinued operations
|
0.09
|
|
|
(0.03
|
)
|
|
0.12
|
|
|
(0.06
|
)
|
Net earnings per share
|
$
|
1.17
|
|
|
$
|
1.18
|
|
|
$
|
2.22
|
|
|
$
|
2.17
|
|
Diluted earnings
/
(loss) per share
|
|
|
|
|
|
|
|
Continuing operations
|
$
|
1.07
|
|
|
$
|
1.21
|
|
|
$
|
2.08
|
|
|
$
|
2.21
|
|
Discontinued operations
|
0.09
|
|
|
(0.03
|
)
|
|
0.12
|
|
|
(0.06
|
)
|
Net earnings per share
|
$
|
1.16
|
|
|
$
|
1.18
|
|
|
$
|
2.20
|
|
|
$
|
2.16
|
|
Weighted average common shares outstanding
|
|
|
|
|
|
|
|
Basic
|
582.2
|
|
|
635.8
|
|
|
590.3
|
|
|
638.3
|
|
Dilutive impact of share-based awards
|
4.6
|
|
|
5.2
|
|
|
5.0
|
|
|
5.4
|
|
Diluted
|
586.8
|
|
|
641.0
|
|
|
595.3
|
|
|
643.7
|
|
Antidilutive shares
|
0.2
|
|
|
—
|
|
|
0.1
|
|
|
—
|
|
Dividends declared per share
|
$
|
0.60
|
|
|
$
|
0.56
|
|
|
$
|
1.16
|
|
|
$
|
1.08
|
|
Note: Per share amounts may not foot due to rounding.
See accompanying Notes to Consolidated Financial Statements.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Comprehensive Income
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
(millions) (unaudited)
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Net earnings
|
$
|
680
|
|
|
$
|
753
|
|
|
$
|
1,312
|
|
|
$
|
1,388
|
|
Other comprehensive income, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
Pension and other benefit liabilities, net of taxes of $3, $5, $8 and $76
|
5
|
|
|
8
|
|
|
12
|
|
|
117
|
|
Currency translation adjustment and cash flow hedges, net of taxes of $0, $1, $1 and $1
|
—
|
|
|
—
|
|
|
5
|
|
|
1
|
|
Other comprehensive income
|
5
|
|
|
8
|
|
|
17
|
|
|
118
|
|
Comprehensive income
|
$
|
685
|
|
|
$
|
761
|
|
|
$
|
1,329
|
|
|
$
|
1,506
|
|
See accompanying Notes to Consolidated Financial Statements.
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Financial Position
|
|
|
|
|
|
|
|
|
(millions)
|
July 30,
2016
|
|
|
January 30,
2016
|
|
|
August 1,
2015
|
|
Assets
|
(unaudited)
|
|
|
|
|
|
(unaudited)
|
|
Cash and cash equivalents, including short term investments of $303, $3,008 and $1,985
|
$
|
1,480
|
|
|
$
|
4,046
|
|
|
$
|
2,742
|
|
Inventory
|
8,631
|
|
|
8,601
|
|
|
8,261
|
|
Current assets of discontinued operations
|
83
|
|
|
322
|
|
|
133
|
|
Other current assets
|
1,309
|
|
|
1,161
|
|
|
2,104
|
|
Total current assets
|
11,503
|
|
|
14,130
|
|
|
13,240
|
|
Property and equipment
|
|
|
|
|
|
|
|
|
Land
|
6,111
|
|
|
6,125
|
|
|
6,120
|
|
Buildings and improvements
|
27,315
|
|
|
27,059
|
|
|
26,726
|
|
Fixtures and equipment
|
5,282
|
|
|
5,347
|
|
|
5,145
|
|
Computer hardware and software
|
2,504
|
|
|
2,617
|
|
|
2,550
|
|
Construction-in-progress
|
232
|
|
|
315
|
|
|
494
|
|
Accumulated depreciation
|
(16,510
|
)
|
|
(16,246
|
)
|
|
(15,452
|
)
|
Property and equipment, net
|
24,934
|
|
|
25,217
|
|
|
25,583
|
|
Noncurrent assets of discontinued operations
|
17
|
|
|
75
|
|
|
420
|
|
Other noncurrent assets
|
834
|
|
|
840
|
|
|
950
|
|
Total assets
|
$
|
37,288
|
|
|
$
|
40,262
|
|
|
$
|
40,193
|
|
Liabilities and shareholders’ investment
|
|
|
|
|
|
|
|
|
Accounts payable
|
$
|
6,811
|
|
|
$
|
7,418
|
|
|
$
|
6,944
|
|
Accrued and other current liabilities
|
3,544
|
|
|
4,236
|
|
|
3,768
|
|
Current portion of long-term debt and other borrowings
|
647
|
|
|
815
|
|
|
841
|
|
Current liabilities of discontinued operations
|
1
|
|
|
153
|
|
|
60
|
|
Total current liabilities
|
11,003
|
|
|
12,622
|
|
|
11,613
|
|
Long-term debt and other borrowings
|
12,063
|
|
|
11,945
|
|
|
11,817
|
|
Deferred income taxes
|
754
|
|
|
823
|
|
|
1,192
|
|
Noncurrent liabilities of discontinued operations
|
19
|
|
|
18
|
|
|
276
|
|
Other noncurrent liabilities
|
1,872
|
|
|
1,897
|
|
|
1,353
|
|
Total noncurrent liabilities
|
14,708
|
|
|
14,683
|
|
|
14,638
|
|
Shareholders’ investment
|
|
|
|
|
|
|
|
|
Common stock
|
48
|
|
|
50
|
|
|
53
|
|
Additional paid-in capital
|
5,562
|
|
|
5,348
|
|
|
5,271
|
|
Retained earnings
|
6,579
|
|
|
8,188
|
|
|
9,099
|
|
Accumulated other comprehensive loss
|
|
|
|
|
|
|
|
|
Pension and other benefit liabilities
|
(576
|
)
|
|
(588
|
)
|
|
(444
|
)
|
Currency translation adjustment and cash flow hedges
|
(36
|
)
|
|
(41
|
)
|
|
(37
|
)
|
Total shareholders’ investment
|
11,577
|
|
|
12,957
|
|
|
13,942
|
|
Total liabilities and shareholders’ investment
|
$
|
37,288
|
|
|
$
|
40,262
|
|
|
$
|
40,193
|
|
Common Stock
Authorized
6,000,000,000
shares,
$.0833
par value;
574,801,225
,
602,226,517
and
630,446,029
shares issued and outstanding at
July 30, 2016
,
January 30, 2016
and
August 1, 2015
, respectively.
Preferred Stock
Authorized
5,000,000
shares,
$.01
par value;
no
shares were issued or outstanding at
July 30, 2016
,
January 30, 2016
or
August 1, 2015
.
See accompanying Notes to Consolidated Financial Statements.
|
|
|
|
|
|
|
|
|
Consolidated Statements of Cash Flows
|
|
|
|
|
Six Months Ended
|
(millions) (unaudited)
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Operating activities
|
|
|
|
|
|
Net earnings
|
$
|
1,312
|
|
|
$
|
1,388
|
|
Earnings / (losses) from discontinued operations, net of tax
|
73
|
|
|
(36
|
)
|
Net earnings from continuing operations
|
1,239
|
|
|
1,424
|
|
Adjustments to reconcile net earnings to cash provided by operations:
|
|
|
|
|
|
Depreciation and amortization
|
1,116
|
|
|
1,090
|
|
Share-based compensation expense
|
67
|
|
|
54
|
|
Deferred income taxes
|
(79
|
)
|
|
(45
|
)
|
Loss on debt extinguishment
|
422
|
|
|
—
|
|
Noncash (gains)
/
losses and other, net
|
(14
|
)
|
|
26
|
|
Changes in operating accounts
|
|
|
|
|
Inventory
|
(29
|
)
|
|
18
|
|
Other assets
|
140
|
|
|
156
|
|
Accounts payable and accrued liabilities
|
(1,466
|
)
|
|
(683
|
)
|
Cash provided by operating activities—continuing operations
|
1,396
|
|
|
2,040
|
|
Cash provided by operating activities—discontinued operations
|
92
|
|
|
823
|
|
Cash provided by operations
|
1,488
|
|
|
2,863
|
|
Investing activities
|
|
|
|
|
|
Expenditures for property and equipment
|
(684
|
)
|
|
(710
|
)
|
Proceeds from disposal of property and equipment
|
14
|
|
|
13
|
|
Proceeds from sale of business
|
—
|
|
|
8
|
|
Other investments
|
1
|
|
|
38
|
|
Cash required for investing activities—continuing operations
|
(669
|
)
|
|
(651
|
)
|
Cash provided by
investing activities—discontinued operations
|
—
|
|
|
19
|
|
Cash required for investing activities
|
(669
|
)
|
|
(632
|
)
|
Financing activities
|
|
|
|
|
|
Additions to long-term debt
|
1,979
|
|
|
—
|
|
Reductions of long-term debt
|
(2,611
|
)
|
|
(54
|
)
|
Dividends paid
|
(666
|
)
|
|
(665
|
)
|
Repurchase of stock
|
(2,238
|
)
|
|
(1,251
|
)
|
Stock option exercises
|
151
|
|
|
271
|
|
Cash required for financing activities
|
(3,385
|
)
|
|
(1,699
|
)
|
Net (decrease)
/
increase in cash and cash equivalents
|
(2,566
|
)
|
|
532
|
|
Cash and cash equivalents at beginning of period
|
4,046
|
|
|
2,210
|
|
Cash and cash equivalents at end of period
|
$
|
1,480
|
|
|
$
|
2,742
|
|
See accompanying Notes to Consolidated Financial Statements.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Shareholders’ Investment
|
|
Common
|
|
|
Stock
|
|
|
Additional
|
|
|
|
|
|
Accumulated Other
|
|
|
|
|
|
Stock
|
|
|
Par
|
|
|
Paid-in
|
|
|
Retained
|
|
|
Comprehensive
|
|
|
|
|
(millions, except per share data)
|
Shares
|
|
|
Value
|
|
|
Capital
|
|
|
Earnings
|
|
|
(Loss)
/
Income
|
|
|
Total
|
|
January 31, 2015
|
640.2
|
|
|
$
|
53
|
|
|
$
|
4,899
|
|
|
$
|
9,644
|
|
|
$
|
(599
|
)
|
|
$
|
13,997
|
|
Net earnings
|
—
|
|
|
—
|
|
|
—
|
|
|
3,363
|
|
|
—
|
|
|
3,363
|
|
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(30
|
)
|
|
(30
|
)
|
Dividends declared
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,378
|
)
|
|
—
|
|
|
(1,378
|
)
|
Repurchase of stock
|
(44.7
|
)
|
|
(4
|
)
|
|
—
|
|
|
(3,441
|
)
|
|
—
|
|
|
(3,445
|
)
|
Stock options and awards
|
6.7
|
|
|
1
|
|
|
449
|
|
|
—
|
|
|
—
|
|
|
450
|
|
January 30, 2016
|
602.2
|
|
|
$
|
50
|
|
|
$
|
5,348
|
|
|
$
|
8,188
|
|
|
$
|
(629
|
)
|
|
$
|
12,957
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings
|
—
|
|
|
—
|
|
|
—
|
|
|
1,312
|
|
|
—
|
|
|
1,312
|
|
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
17
|
|
|
17
|
|
Dividends declared
|
—
|
|
|
—
|
|
|
—
|
|
|
(680
|
)
|
|
—
|
|
|
(680
|
)
|
Repurchase of stock
|
(30.4
|
)
|
|
(2
|
)
|
|
—
|
|
|
(2,241
|
)
|
|
—
|
|
|
(2,243
|
)
|
Stock options and awards
|
3.0
|
|
|
—
|
|
|
214
|
|
|
—
|
|
|
—
|
|
|
214
|
|
July 30, 2016
|
574.8
|
|
|
$
|
48
|
|
|
$
|
5,562
|
|
|
$
|
6,579
|
|
|
$
|
(612
|
)
|
|
$
|
11,577
|
|
See accompanying Notes to Consolidated Financial Statements.
Notes to Consolidated Financial Statements (unaudited)
1. Accounting Policies
These financial statements should be read in conjunction with the financial statement disclosures in our
2015
Form 10-K. We use the same accounting policies in preparing quarterly and annual financial statements. All adjustments necessary for a fair presentation of quarterly operating results are reflected herein and are of a normal, recurring nature. Certain prior-year amounts have been reclassified to conform to the current year presentation. Unless otherwise noted, amounts presented within the Notes to Consolidated Financial Statements refer to our continuing operations.
Due to the seasonal nature of our business, quarterly revenues, expenses, earnings, and cash flows are not necessarily indicative of the results that may be expected for the full year.
2. Discontinued Operations
As part of a March 2016 settlement between Target Canada Co. and certain other wholly owned subsidiaries of Target (collectively Canada Subsidiaries) and all of their former landlords, we agreed to subordinate a portion of our intercompany claims and make certain cash contributions to the Target Canada Co. estate in exchange for a full release from our obligations under guarantees of certain leases of the Canada Subsidiaries. The settlement was contingent upon the Canada Subsidiaries' creditors' and the court's approval of a plan of compromise and arrangement to complete the controlled, orderly, and timely wind-down of the Canada Subsidiaries (Plan). During the second quarter of 2016, a Plan was approved. The net pretax financial impact of the settlement and Plan was materially consistent with amounts previously recorded in our financial statements. For the three and six months ended July 30, 2016, net earnings from discontinued operations primarily reflect tax benefits from investment losses in Canada recognized upon court approval of the Canada Subsidiaries' liquidation plan. During the second quarter of 2016, we made cash contributions of
$27 million
to the Target Canada Co. estate and received cash distributions of
$160 million
.
|
|
|
|
|
|
|
|
|
|
|
Assets and Liabilities of Discontinued Operations
|
(millions)
|
July 30,
2016
|
|
January 30,
2016
|
|
August 1,
2015
|
|
Income tax benefit
|
$
|
41
|
|
$
|
77
|
|
$
|
234
|
|
Receivables from Canada Subsidiaries
|
59
|
|
320
|
|
319
|
|
Total assets
|
$
|
100
|
|
$
|
397
|
|
$
|
553
|
|
|
|
|
|
Accrued liabilities
|
$
|
20
|
|
$
|
171
|
|
$
|
336
|
|
Total liabilities
|
$
|
20
|
|
$
|
171
|
|
$
|
336
|
|
3. Restructuring Initiatives
In 2015, we initiated a series of headquarters workforce reductions intended to increase organizational effectiveness and provide cost savings that can be reinvested in our growth initiatives. As a result, we recorded
$11 million
and
$114 million
of severance and other benefits-related charges within selling, general, and administrative expenses (SG&A) during the three and six months ended August 1, 2015. The vast majority of these expenses required cash expenditures and were not included in our segment results. An accrual for restructuring costs of
$14 million
was included in other current liabilities as of August 1, 2015.
No
balance remained as of July 30, 2016.
4. Fair Value Measurements
Fair value measurements are reported in one of three levels based on the lowest level of significant input used: Level 1 (unadjusted quoted prices in active markets); Level 2 (observable market inputs, other than quoted prices included in Level 1); and Level 3 (unobservable inputs that cannot be corroborated by observable market data).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements - Recurring Basis
|
|
Fair Value at
|
(millions)
|
Pricing Category
|
July 30,
2016
|
|
|
January 30,
2016
|
|
|
August 1,
2015
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
|
|
|
|
|
Short-term investments
|
Level 1
|
$
|
303
|
|
|
$
|
3,008
|
|
|
$
|
1,985
|
|
Other current assets
|
|
|
|
|
|
|
|
|
|
Prepaid forward contracts
|
Level 1
|
31
|
|
|
32
|
|
|
36
|
|
Beneficial interest asset
|
Level 3
|
13
|
|
|
19
|
|
|
29
|
|
Interest rate swaps
(a)
|
Level 2
|
—
|
|
|
12
|
|
|
25
|
|
Other noncurrent assets
|
|
|
|
|
|
|
|
|
|
Interest rate swaps
(a)
|
Level 2
|
28
|
|
|
27
|
|
|
16
|
|
Beneficial interest asset
|
Level 3
|
6
|
|
|
12
|
|
|
19
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
Other current liabilities
|
|
|
|
|
|
|
|
|
|
Interest rate swaps
(a)
|
Level 2
|
—
|
|
|
8
|
|
|
16
|
|
(a)
See Note 7 for additional information on interest rate swaps.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant Financial Instruments not Measured at Fair Value
(a)
(millions)
|
July 30, 2016
|
|
January 30, 2016
|
|
August 1, 2015
|
Carrying
Amount
|
|
Fair
Value
|
|
|
Carrying
Amount
|
|
Fair
Value
|
|
|
Carrying
Amount
|
|
Fair
Value
|
|
Debt
(b)
|
$
|
11,712
|
|
$
|
13,542
|
|
|
$
|
11,859
|
|
$
|
13,385
|
|
|
$
|
11,854
|
|
$
|
13,365
|
|
(a)
The carrying amounts of certain other current assets, accounts payable, and certain accrued and other current liabilities approximate fair value due to their short-term nature.
(b)
The carrying amount and estimated fair value of debt exclude unamortized swap valuation adjustments and capital lease obligations.
5. Notes Payable and Long-Term Debt
We obtain short-term financing from time to time under our commercial paper program, a form of notes payable. No balances were outstanding at any time during 2016 or 2015.
In April 2016, we issued unsecured fixed rate debt of
$1 billion
at
2.5%
that matures in April 2026 and
$1 billion
at
3.625%
that matures in April 2046. During the first and second quarter of 2016, we used cash on hand and proceeds from these issuances to repurchase
$565 million
and
$824 million
of debt, respectively, before its maturity at a market value of
$820 million
and
$981 million
, respectively. We recognized a loss on early retirement of approximately
$261 million
and
$161 million
in first and second quarter, respectively, which was recorded in net interest expense in our Consolidated Statements of Operations.
6. Data Breach
In prior periods we have separately reported on our accrual for estimated probable losses and cumulative expenses with respect to the data breach we experienced in the fourth quarter of 2013 (the Data Breach). As of the date of this filing we have resolved the most significant claims relating to the Data Breach and there were no material changes to our loss contingency assessment relating to the few remaining claims during the second quarter. We do not expect there to be any material changes to the assessment of our exposure from this event, and we will no longer be providing separate reporting with respect to the Data Breach.
7. Derivative Financial Instruments
Our derivative instruments primarily consist of interest rate swaps, which are used to mitigate interest rate risk. As a result of our use of derivative instruments, we have counterparty credit exposure to large global financial institutions. We monitor this concentration of counterparty credit risk on an ongoing basis. See Note 4 for a description of the fair value measurement of our derivative instruments and their classification on the Consolidated Statements of Financial Position.
As of
July 30, 2016
and
August 1, 2015
, interest rate swaps with notional amounts totaling
$1,000 million
and
$1,250 million
, respectively, were designated as fair value hedges.
No
ineffectiveness was recognized during the three months ended
July 30, 2016
or
August 1, 2015
.
Periodic payments, valuation adjustments, and amortization of gains or losses on our derivative contracts had the following effect on our Consolidated Statements of Operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Contracts - Effect on Results of Operations
(millions)
|
Three Months Ended
|
|
Six Months Ended
|
Type of Contract
|
|
Classification of (Income)/Expense
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Interest rate swaps
|
|
Net interest expense
|
$
|
(8
|
)
|
|
$
|
(9
|
)
|
|
$
|
(16
|
)
|
|
$
|
(18
|
)
|
The amount remaining on unamortized hedged debt valuation gains from terminated or de-designated interest rate swaps that will be amortized into earnings over the remaining lives of the underlying debt totaled
$8 million
,
$15 million
, and
$25 million
, at
July 30, 2016
,
January 30, 2016
, and
August 1, 2015
, respectively.
8. Share Repurchase
Under our current
$10 billion
share repurchase program, we have repurchased
125.0 million
shares of common stock through
July 30, 2016
at an average price of
$70.57
, for a total investment of
$8.8 billion
.
|
|
|
|
|
|
|
|
|
Share Repurchases
|
Six Months Ended
(a)
|
(millions, except per share data)
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Total number of shares purchased
|
30.4
|
|
|
15.2
|
|
Average price paid per share
|
$
|
73.70
|
|
|
$
|
81.41
|
|
Total investment
|
$
|
2,243
|
|
|
$
|
1,240
|
|
Note: Excludes shares withheld to settle employee statutory tax withholding related to the vesting of share-based awards.
(a)
Includes
0.2 million
and
0.1 million
shares delivered upon the noncash settlement of prepaid contracts during the six months ended July 30, 2016 and August 1, 2015, respectively. These contracts had an original cash investment of
$12 million
and
$3 million
, respectively, and aggregate market value of
$13 million
and
$7 million
. These contracts are among the investment vehicles used to reduce our economic exposure related to our nonqualified deferred compensation plans. Note 10 provides the details of our positions in prepaid forward contracts.
9. Share-Based Compensation
During the first quarter of 2016, we adopted Accounting Standards Update (ASU) No. 2016-09,
Improvements to Employee Share-Based Payment Accounting
(ASU 2016-09). As a result of adoption, we recognized
$1 million
and
$18 million
of excess tax benefits related to share-based payments in our provision for income taxes for the three and six months ended July 30, 2016. These items were historically recorded in additional paid-in capital. In addition, for each period presented, cash flows related to excess tax benefits are classified as an operating activity along with other income tax cash flows. Cash paid on employees' behalf related to shares withheld for tax purposes is classified as a financing activity. Retrospective application of the cash flow presentation requirements resulted in increases to both net cash provided by operations and net cash required for financing activities of
$74 million
for the six months ended August 1, 2015. Our compensation expense each period continues to reflect estimated forfeitures.
10. Pension and Other Benefits
Pension Benefits
We provide pension plan benefits to certain eligible team members.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Pension Benefits Expense
|
Three Months Ended
|
|
Six Months Ended
|
(millions)
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Service cost
|
$
|
20
|
|
|
$
|
27
|
|
|
$
|
41
|
|
|
$
|
55
|
|
Interest cost
|
35
|
|
|
39
|
|
|
69
|
|
|
77
|
|
Expected return on assets
|
(65
|
)
|
|
(65
|
)
|
|
(129
|
)
|
|
(130
|
)
|
Amortization of losses
|
13
|
|
|
19
|
|
|
25
|
|
|
42
|
|
Amortization of prior service cost
|
(3
|
)
|
|
(3
|
)
|
|
(6
|
)
|
|
(6
|
)
|
Settlement charges
|
—
|
|
|
—
|
|
|
—
|
|
|
2
|
|
Total
|
$
|
—
|
|
|
$
|
17
|
|
|
$
|
—
|
|
|
$
|
40
|
|
Other Benefits
We offer unfunded nonqualified deferred compensation plans to certain team members. We mitigate some of our risk of these plans through investing in vehicles, including company-owned life insurance and prepaid forward contracts in our own common stock, that offset a substantial portion of our economic exposure to the returns of these plans. These investment vehicles are general corporate assets and are marked to market with the related gains and losses recognized in the Consolidated Statements of Operations in the period they occur.
The total change in fair value for contracts indexed to our own common stock recognized in earnings was pretax (loss)/income of
($2) million
and
$1 million
for the three and six months ended
July 30, 2016
, respectively, and pretax income of
$1 million
and
$4 million
for the three and six months ended
August 1, 2015
, respectively. During the
six
months ended
July 30, 2016
and
August 1, 2015
, we made
no
investments in prepaid forward contracts in our own common stock. Adjusting our position in these investment vehicles may involve repurchasing shares of Target common stock when settling the forward contracts as described in Note 8. The settlement dates of these instruments are regularly renegotiated with the counterparty. At
July 30, 2016
, January 30, 2016 and August 1, 2015, we held asset positions in prepaid forward contracts for
0.4 million
shares of our common stock, for a total cash investment of
$17 million
,
$18 million
and
$18 million
(
$41.11
per share) and a contractual fair value of
$31 million
,
$32 million
and
$36 million
, respectively.
11. Accumulated Other Comprehensive (Loss)
/ Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(millions)
|
Cash Flow
Hedges
|
|
|
Currency
Translation
Adjustment
|
|
|
Pension and
Other
Benefits
|
|
|
Total
|
|
January 30, 2016
|
$
|
(19
|
)
|
|
$
|
(22
|
)
|
|
$
|
(588
|
)
|
|
$
|
(629
|
)
|
Other comprehensive income before reclassifications
|
—
|
|
|
2
|
|
|
3
|
|
|
5
|
|
Amounts reclassified from AOCI
|
3
|
|
(a)
|
—
|
|
|
9
|
|
(b)
|
12
|
|
July 30, 2016
|
$
|
(16
|
)
|
|
$
|
(20
|
)
|
|
$
|
(576
|
)
|
|
$
|
(612
|
)
|
(a)
Represents gains and losses on cash flow hedges, net of
$1 million
of taxes.
(b)
Represents amortization of pension and other benefit liabilities, net of
$6 million
of taxes.
12. Segment Reporting
Our segment measure of profit is used by management to evaluate performance and make operating decisions. We operate as a single segment that includes all of our continuing operations, which are designed to enable guests to purchase products seamlessly in stores, online or through mobile devices.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Segment Results
|
Three Months Ended
|
|
Six Months Ended
|
(millions)
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Sales
|
$
|
16,169
|
|
|
$
|
17,427
|
|
|
$
|
32,364
|
|
|
$
|
34,546
|
|
Cost of sales
|
11,102
|
|
|
12,051
|
|
|
22,286
|
|
|
23,962
|
|
Gross margin
|
5,067
|
|
|
5,376
|
|
|
10,078
|
|
|
10,584
|
|
Selling, general, and administrative expenses
(d)
|
3,256
|
|
|
3,475
|
|
|
6,398
|
|
|
6,883
|
|
Depreciation and amortization
|
570
|
|
|
551
|
|
|
1,116
|
|
|
1,090
|
|
Segment profit
|
1,241
|
|
|
1,350
|
|
|
2,564
|
|
|
2,611
|
|
Restructuring costs
(a)(d)
|
—
|
|
|
(11
|
)
|
|
—
|
|
|
(114
|
)
|
Pharmacy transaction-related costs
(b)(d)
|
7
|
|
|
—
|
|
|
(4
|
)
|
|
—
|
|
Data Breach-related costs
(c)(d)
|
—
|
|
|
(9
|
)
|
|
—
|
|
|
(12
|
)
|
Earnings from continuing operations before interest expense and income taxes
|
1,248
|
|
|
1,330
|
|
|
2,560
|
|
|
2,485
|
|
Net interest expense
|
307
|
|
|
148
|
|
|
722
|
|
|
305
|
|
Earnings from continuing operations before income taxes
|
$
|
941
|
|
|
$
|
1,182
|
|
|
$
|
1,838
|
|
|
$
|
2,180
|
|
Note: Amounts may not foot due to rounding.
(a)
Refer to Note 3 for more information on restructuring costs.
(b)
Represents contract termination charges, severance and other items related to the December 2015 sale of our former pharmacy and clinic businesses to CVS.
(c)
Refer to Note 6 for more information on Data Breach-related costs.
(d)
The sum of segment SG&A expenses, restructuring costs, pharmacy transaction-related costs, and Data Breach-related costs equal consolidated SG&A expenses.
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Segment Assets to Total Assets
(millions)
|
July 30,
2016
|
|
|
January 30,
2016
|
|
|
August 1,
2015
|
|
Segment assets
|
$
|
37,182
|
|
|
$
|
39,845
|
|
|
$
|
39,585
|
|
Assets of discontinued operations
|
100
|
|
|
397
|
|
|
553
|
|
Unallocated assets
(a)
|
6
|
|
|
20
|
|
|
55
|
|
Total assets
|
$
|
37,288
|
|
|
$
|
40,262
|
|
|
$
|
40,193
|
|
(a)
Represents the insurance receivable related to the Data Breach.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Executive Summary
Second
quarter
2016
includes the following notable items:
|
|
•
|
GAAP earnings per share from continuing operations were
$1.07
, including a loss on early retirement of debt of $0.17.
|
|
|
•
|
Adjusted earnings per share from continuing operations were
$1.23
.
|
|
|
•
|
Second quarter comparable sales decreased
(1.1)
percent, driven by a
(2.2)
percent decline in traffic and 1.1 percent increase in average transaction amount.
|
|
|
•
|
We returned $1.7 billion to shareholders in the second quarter through dividends and share repurchase.
|
Sales were
$16,169 million
for the three months ended
July 30, 2016
, a decrease of
$1,258 million
or
7.2
percent from the same period in the prior year. The decrease is due to the December 2015 sale of our pharmacy and clinic businesses (Pharmacy Transaction), which generated $1,055 million of sales during the three months ended August 1, 2015, and by a decrease in comparable sales. Operating cash flow provided by continuing operations was
$1,396 million
and
$2,040 million
for the
six
months ended
July 30, 2016
and
August 1, 2015
, respectively. The decrease is due to the payment of approximately $500 million of taxes during the first quarter of 2016, primarily related to the Pharmacy Transaction.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share from Continuing Operations
|
Three Months Ended
|
|
|
|
|
Six Months Ended
|
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
Change
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
Change
|
|
GAAP diluted earnings per share
|
$
|
1.07
|
|
|
$
|
1.21
|
|
|
(11.6
|
)%
|
|
$
|
2.08
|
|
|
$
|
2.21
|
|
|
(5.9
|
)%
|
Adjustments
|
0.16
|
|
|
0.01
|
|
|
|
|
0.43
|
|
|
0.11
|
|
|
|
|
Adjusted diluted earnings per share
|
$
|
1.23
|
|
|
$
|
1.22
|
|
|
0.5
|
%
|
|
$
|
2.51
|
|
|
$
|
2.32
|
|
|
8.2
|
%
|
Note: Amounts may not foot due to rounding. Adjusted diluted earnings per share from continuing operations (Adjusted EPS), a non-GAAP metric, excludes the impact of certain matters not related to our routine retail operations and the impact of our discontinued Canadian operations. Management believes that Adjusted EPS is meaningful to provide period-to-period comparisons of our operating results. A reconciliation of non-GAAP financial measures to GAAP measures is provided on page 17.
We report after-tax return on invested capital (ROIC) from continuing operations as we believe ROIC provides a meaningful measure of the effectiveness of our capital allocation over time. For the trailing twelve months ended
July 30, 2016
, ROIC was
15.8
percent, compared with
13.3
percent for the trailing twelve months ended
August 1, 2015
. Excluding the net gain on the Pharmacy Transaction, ROIC was 13.7 percent for the trailing twelve months ended
July 30, 2016
. A reconciliation of ROIC is provided on page 18.
Analysis of Results of Operations
Segment Results
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
Six Months Ended
|
|
|
|
(dollars in millions)
|
July 30,
2016
|
|
|
August 1,
2015
(a)
|
|
|
Percent
Change
|
|
|
July 30,
2016
|
|
|
August 1,
2015
(a)
|
|
|
Percent
Change
|
|
Sales
|
$
|
16,169
|
|
|
$
|
17,427
|
|
|
(7.2
|
)%
|
|
$
|
32,364
|
|
|
$
|
34,546
|
|
|
(6.3
|
)%
|
Cost of sales
|
11,102
|
|
|
12,051
|
|
|
(7.9
|
)
|
|
22,286
|
|
|
23,962
|
|
|
(7.0
|
)
|
Gross margin
|
5,067
|
|
|
5,376
|
|
|
(5.7
|
)
|
|
10,078
|
|
|
10,584
|
|
|
(4.8
|
)
|
SG&A expenses
(b)
|
3,256
|
|
|
3,475
|
|
|
(6.3
|
)
|
|
6,398
|
|
|
6,883
|
|
|
(7.1
|
)
|
EBITDA
|
1,811
|
|
|
1,901
|
|
|
(4.7
|
)
|
|
3,680
|
|
|
3,701
|
|
|
(0.6
|
)
|
Depreciation and amortization
|
570
|
|
|
551
|
|
|
3.6
|
|
|
1,116
|
|
|
1,090
|
|
|
2.4
|
|
EBIT
|
$
|
1,241
|
|
|
$
|
1,350
|
|
|
(8.1
|
)%
|
|
$
|
2,564
|
|
|
$
|
2,611
|
|
|
(1.8
|
)%
|
Note: We operate as a single segment which includes all of our continuing operations, excluding net interest expense and certain other discretely managed items. Our segment operations are designed to enable guests to purchase products seamlessly in stores, online, or through mobile devices. See Note 12 of our Financial Statements for a reconciliation of our segment results to earnings before income taxes.
(a)
Sales include $1,055 million and $2,128 million related to our former pharmacy and clinic businesses for the three and six months ended August 1, 2015, respectively, and cost of sales include $840 million and $1,687 million, respectively. The December 2015 sale of these businesses to CVS had no notable impact on EBITDA or EBIT.
(b)
SG&A includes
$163 million
and
$321 million
of net profit-sharing income under our credit card program agreement for the three and six months ended
July 30, 2016
, respectively, and
$159 million
and
$311 million
for the three and six months ended
August 1, 2015
, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
Rate Analysis
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Gross margin rate
|
31.3
|
%
|
|
30.9
|
%
|
|
31.1
|
%
|
|
30.6
|
%
|
SG&A expense rate
|
20.1
|
|
|
19.9
|
|
|
19.8
|
|
|
19.9
|
|
EBITDA margin rate
(a)
|
11.2
|
|
|
10.9
|
|
|
11.4
|
|
|
10.7
|
|
Depreciation and amortization expense rate
|
3.5
|
|
|
3.2
|
|
|
3.4
|
|
|
3.2
|
|
EBIT margin rate
(a)
|
7.7
|
|
|
7.7
|
|
|
7.9
|
|
|
7.6
|
|
Note: Rate analysis metrics are computed by dividing the applicable amount by sales.
(a)
Excluding sales of our former pharmacy and clinic businesses, EBITDA margin rates were 11.6 percent and 11.4 percent for the three and six months ended August 1, 2015, respectively, and EBIT margin rates were 8.2 percent and 8.1 percent, respectively.
Sales
Sales include merchandise sales, net of expected returns, from our stores and digital channels, and gift card breakage. Digital channel sales include all sales initiated through mobile applications and our conventional websites. Digital channel sales may be fulfilled through our distribution centers or our stores.
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales by Channel
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
(a)
|
|
|
July 30,
2016
|
|
|
August 1,
2015
(a)
|
|
Stores
|
96.7
|
%
|
|
97.3
|
%
|
|
96.6
|
%
|
|
97.2
|
%
|
Digital
|
3.3
|
|
|
2.7
|
|
|
3.4
|
|
|
2.8
|
|
Total
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
(a)
Excluding sales of our former pharmacy and clinic businesses, stores and digital channels sales were 97.1 percent and 2.9 percent of total sales, respectively, for both the three and six months ended August 1, 2015.
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales by Product Category
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Household essentials
(a)
|
23
|
%
|
|
28
|
%
|
|
23
|
%
|
|
28
|
%
|
Food and pet supplies
|
22
|
|
|
20
|
|
|
23
|
|
|
21
|
|
Apparel and accessories
|
22
|
|
|
21
|
|
|
21
|
|
|
20
|
|
Home furnishings and décor
|
19
|
|
|
17
|
|
|
18
|
|
|
17
|
|
Hardlines
|
14
|
|
|
14
|
|
|
15
|
|
|
14
|
|
Total
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
(a)
Pharmacy represented six percent of total sales for the three and six months ended August 1, 2015.
Comparable sales is a measure that highlights the performance of our stores and digital channels by measuring the change in sales for a period over the comparable, prior-year period of equivalent length. Comparable sales include all sales, except sales from stores open less than 13 months, digital acquisitions operating less than one year, stores that have been closed, and digital acquisitions that we no longer operate. We removed pharmacy and clinic sales from the 2015 sales amounts when calculating 2016 comparable sales. Comparable sales measures vary across the retail industry. As a result, our comparable sales calculation is not necessarily comparable to similarly titled measures reported by other companies.
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparable Sales
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Comparable sales change
|
(1.1
|
)%
|
|
2.4
|
%
|
|
—
|
%
|
|
2.4
|
%
|
Drivers of change in comparable sales
|
|
|
|
|
|
|
|
|
|
|
|
Number of transactions
|
(2.2
|
)
|
|
1.6
|
|
|
(0.9
|
)
|
|
1.3
|
|
Average transaction amount
|
1.1
|
|
|
0.8
|
|
|
1.0
|
|
|
1.1
|
|
Selling price per unit
|
2.6
|
|
|
3.8
|
|
|
2.8
|
|
|
4.5
|
|
Units per transaction
|
(1.5
|
)
|
|
(2.9
|
)
|
|
(1.7
|
)
|
|
(3.2
|
)
|
Note: Amounts may not foot due to rounding.
|
|
|
|
|
|
|
|
|
|
|
|
|
Contribution to Comparable Sales Change
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Stores channel comparable sales change
|
(1.6
|
)%
|
|
1.8
|
%
|
|
(0.5
|
)%
|
|
1.7
|
%
|
Digital channel contribution to comparable sales change
|
0.5
|
|
|
0.6
|
|
|
0.6
|
|
|
0.7
|
|
Total comparable sales change
|
(1.1
|
)%
|
|
2.4
|
%
|
|
—
|
%
|
|
2.4
|
%
|
Note: Amounts may not foot due to rounding.
The collective interaction of a broad array of macroeconomic, competitive, and consumer behavioral factors, as well as sales mix, and transfer of sales to new stores makes further analysis of sales metrics infeasible.
We monitor the percentage of sales that are paid for using REDcards (REDcard Penetration) because our internal analysis has indicated that a meaningful portion of the incremental purchases on REDcards are also incremental sales for Target, with the remainder representing a shift in tender type. Guests receive a 5 percent discount on virtually all purchases when they use a REDcard at Target.
|
|
|
|
|
|
|
|
|
|
|
|
|
REDcard Penetration
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Target Debit Card
|
12.7
|
%
|
|
12.0
|
%
|
|
12.9
|
%
|
|
12.0
|
%
|
Target Credit Cards
|
11.1
|
|
|
10.1
|
|
|
10.7
|
|
|
9.8
|
|
Total REDcard Penetration
|
23.9
|
%
|
|
22.1
|
%
|
|
23.6
|
%
|
|
21.8
|
%
|
Note: Excluding pharmacy and clinic sales, total REDcard penetration was 23.2 percent and 22.9 percent for the three and six months ended August 1, 2015, respectively. Amounts may not foot due to rounding.
Gross Margin Rate
For the three and six months ended
July 30, 2016
, our gross margin rate was
31.3
percent and
31.1 percent
, respectively, compared with
30.9
percent and
30.6 percent
in the comparable period last year. The increase was primarily due to the Pharmacy Transaction, partially offset by increased shipping costs. Cost of goods savings helped offset the impact of a competitive promotional environment.
Selling, General, and Administrative Expense Rate
For the three and six months ended
July 30, 2016
, our SG&A expense rate was
20.1
percent and
19.8 percent
, respectively, compared to
19.9
percent in the comparable periods last year. For the three and six months ended July 30, 2016, the benefit of the Pharmacy Transaction and technology-related cost savings was offset by investments in our team and other items. Other items include the impact of other broad-based cost savings initiatives that were more than offset by broad-based reinvestment in our business and, for the three months ended, the deleveraging impact of the decline in sales.
Store Data
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in Number of Stores
|
Three Months Ended
|
|
Six Months Ended
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
Beginning store count
|
1,793
|
|
|
1,795
|
|
|
1,792
|
|
|
1,790
|
|
Opened
|
5
|
|
|
4
|
|
|
6
|
|
|
9
|
|
Closed
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
Ending store count
|
1,797
|
|
|
1,799
|
|
|
1,797
|
|
|
1,799
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Stores and
Retail Square Feet
|
Number of Stores
|
|
Retail Square Feet
(a)
|
July 30,
2016
|
|
January 30,
2016
|
|
August 1,
2015
|
|
|
July 30,
2016
|
|
January 30,
2016
|
|
August 1,
2015
|
|
170,000 or more sq. ft.
|
278
|
|
278
|
|
280
|
|
|
49,688
|
|
49,688
|
|
50,036
|
|
50,000 to 169,999 sq. ft.
|
1,505
|
|
1,505
|
|
1,514
|
|
|
189,732
|
|
189,677
|
|
190,608
|
|
49,999 or less sq. ft.
|
14
|
|
9
|
|
5
|
|
|
300
|
|
174
|
|
92
|
|
Total
|
1,797
|
|
1,792
|
|
1,799
|
|
|
239,720
|
|
239,539
|
|
240,736
|
|
(a)
In thousands; reflects total square feet, less office, distribution center, and vacant space.
Other Performance Factors
Consolidated Selling, General, and Administrative Expenses
We recorded $(7) million and $4 million of selling, general, and administrative expenses outside of the segment during the three and six months ended
July 30, 2016
, respectively, and $20 million and $126 million for the three and six months ended and
August 1, 2015
, respectively, because they are discretely managed. Additional information about these items is provided within the Reconciliation of Non-GAAP Financial Measures to GAAP Measures on page 17 and Note 12 of the Financial Statements.
Net Interest Expense
Net interest expense from continuing operations was
$307 million
and
$722 million
for the three and six months ended
July 30, 2016
, compared to
$148 million
and
$305 million
for the three and six months ended
August 1, 2015
. Net interest expense for the three and six months ended
July 30, 2016
included a loss on early retirement of debt of
$161 million
and
$422 million
, respectively.
Provision for Income Taxes
Our effective income tax rate from continuing operations for the three and six months ended
July 30, 2016
was
33.6
percent and
32.6 percent
, respectively, compared with
34.6
percent and
34.7 percent
for the three and six months ended
August 1, 2015
, respectively. For the three months ended July 30, 2016, the decrease was primarily due to lower pretax earnings as a result of the loss on early retirement of debt. The lower pretax earnings decreased our effective income tax rate by increasing the rate impact of recurring tax deductions. For the six months ended July 30, 2016, the decrease was also due to the recognition of $18 million of excess tax benefits related to share-based payments after the adoption of ASU 2016-09. Refer to Note 9 of the Financial Statements for more information regarding ASU 2016-09.
Discontinued Operations
See Note 2 of the Financial Statements for information regarding our Canada exit.
Reconciliation of Non-GAAP Financial Measures to GAAP Measures
To provide additional transparency, we have disclosed non-GAAP adjusted diluted earnings per share from continuing operations (Adjusted EPS). This metric excludes certain items presented below. We believe this information is useful in providing period-to-period comparisons of the results of our continuing operations. This measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States. The most comparable GAAP measure is diluted earnings per share from continuing operations. Adjusted EPS should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Other companies may calculate Adjusted EPS differently than we do, limiting the usefulness of the measure for comparisons with other companies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EPS
|
|
Three Months Ended
|
|
|
July 30, 2016
|
|
August 1, 2015
|
(millions, except per share data)
|
|
Pretax
|
|
|
Net of Tax
|
|
|
Per Share Amounts
|
|
|
Pretax
|
|
|
Net of Tax
|
|
|
Per Share Amounts
|
|
GAAP diluted earnings per share from continuing operations
|
|
|
|
|
|
$
|
1.07
|
|
|
|
|
|
|
$
|
1.21
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on early retirement of debt
|
|
$
|
161
|
|
|
$
|
98
|
|
|
$
|
0.17
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Restructuring costs
(a)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11
|
|
|
8
|
|
|
0.01
|
|
Other
(b)
|
|
(7
|
)
|
|
(4
|
)
|
|
(0.01
|
)
|
|
9
|
|
|
5
|
|
|
0.01
|
|
Resolution of income tax matters
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(5
|
)
|
|
(0.01
|
)
|
Adjusted diluted earnings per share from continuing operations
|
|
|
|
|
|
$
|
1.23
|
|
|
|
|
|
|
$
|
1.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
July 30, 2016
|
|
August 1, 2015
|
(millions, except per share data)
|
|
Pretax
|
|
|
Net of Tax
|
|
|
Per Share Amounts
|
|
|
Pretax
|
|
|
Net of Tax
|
|
|
Per Share Amounts
|
|
GAAP diluted earnings per share from continuing operations
|
|
|
|
|
|
$
|
2.08
|
|
|
|
|
|
|
$
|
2.21
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on early retirement of debt
|
|
$
|
422
|
|
|
$
|
257
|
|
|
$
|
0.43
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Restructuring costs
(a)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
114
|
|
|
72
|
|
|
0.11
|
|
Other
(b)
|
|
4
|
|
|
3
|
|
|
—
|
|
|
12
|
|
|
7
|
|
|
0.01
|
|
Resolution of income tax matters
|
|
—
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
(8
|
)
|
|
(0.01
|
)
|
Adjusted diluted earnings per share from continuing operations
|
|
|
|
|
|
$
|
2.51
|
|
|
|
|
|
|
$
|
2.32
|
|
Note: Amounts may not foot due to rounding.
(a)
Refer to Note 3 of the Financial Statements.
(b)
For the three and six months ended July 30, 2016, represents contract termination charges, severance and other items related to the Pharmacy Transaction. For the
three and six
months ended August 1, 2015, represents costs related to the 2013 data breach.
We have also disclosed after-tax return on invested capital from continuing operations (ROIC), which is a ratio based on GAAP information, with the exception of adjustments made to capitalize operating leases. Operating leases are capitalized as part of the ROIC calculation to control for differences in capital structure between us and our competitors. We believe this metric provides a meaningful measure of the effectiveness of our capital allocation over time. Other companies may calculate ROIC differently than we do, limiting the usefulness of the measure for comparisons with other companies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
After-Tax Return on Invested Capital
|
|
|
|
|
|
|
|
Numerator
|
|
Trailing Twelve Months
|
|
|
(dollars in millions)
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
|
Earnings from continuing operations before interest expense and income taxes
|
|
$
|
5,605
|
|
|
$
|
4,974
|
|
|
|
+ Operating lease interest
(a)(b)
|
|
77
|
|
|
90
|
|
|
|
Adjusted earnings from continuing operations before interest expense and income taxes
|
|
5,682
|
|
|
5,064
|
|
|
|
- Income tax effect
(c)
|
|
1,791
|
|
|
1,694
|
|
|
|
Net operating profit after taxes
|
|
$
|
3,891
|
|
|
$
|
3,370
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator
(dollars in millions)
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
August 2,
2014
|
|
Current portion of long-term debt and other borrowings
|
|
$
|
647
|
|
|
$
|
841
|
|
|
$
|
294
|
|
+ Noncurrent portion of long-term debt
|
|
12,063
|
|
|
11,817
|
|
|
12,551
|
|
+ Shareholders' equity
|
|
11,577
|
|
|
13,942
|
|
|
16,433
|
|
+ Capitalized operating lease obligations
(b)(d)
|
|
1,274
|
|
|
1,497
|
|
|
1,573
|
|
- Cash and cash equivalents
|
|
1,480
|
|
|
2,742
|
|
|
766
|
|
- Net assets of discontinued operations
|
|
80
|
|
|
217
|
|
|
4,653
|
|
Invested capital
|
|
$
|
24,001
|
|
|
$
|
25,138
|
|
|
$
|
25,432
|
|
Average invested capital
(e)
|
|
$
|
24,569
|
|
|
$
|
25,286
|
|
|
|
|
|
|
|
|
|
|
|
|
|
After-tax return on invested capital
(f)
|
|
15.8
|
%
|
|
13.3
|
%
|
|
|
(a)
Represents the add-back to operating income driven by the hypothetical capitalization of our operating leases, using eight times our trailing twelve months rent expense and an estimated interest rate of six percent.
(b)
See the following Reconciliation of Capitalized Operating Leases table for the adjustments to our GAAP total rent expense to obtain the hypothetical capitalization of operating leases and related operating lease interest.
(c)
Calculated using the effective tax rate for continuing operations, which was
31.5%
and
33.4%
for the trailing twelve months ended
July 30, 2016
and
August 1, 2015
. For the trailing twelve months ended July 30, 2016 and August 1, 2015, includes tax effect of $1,767 million and $1,664 million, respectively, related to EBIT and $24 million and $30 million, respectively, related to operating lease interest.
(d)
Calculated as eight times our trailing twelve months rent expense.
(e)
Average based on the invested capital at the end of the current period and the invested capital at the end of the comparable prior period.
(f)
Excluding the net gain on the Pharmacy Transaction, ROIC was 13.7 percent for the trailing twelve months ended
July 30, 2016
.
Capitalized operating lease obligations and operating lease interest are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. The most comparable GAAP measure is total rent expense. Capitalized operating lease obligations and operating lease interest should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Capitalized Operating Leases
|
|
Trailing Twelve Months
|
(dollars in millions)
|
|
July 30,
2016
|
|
|
August 1,
2015
|
|
|
August 2,
2014
|
|
Total rent expense
|
|
$
|
159
|
|
|
$
|
187
|
|
|
$
|
197
|
|
Capitalized operating lease obligations (total rent expense x 8)
|
|
1,274
|
|
|
1,497
|
|
|
1,573
|
|
Operating lease interest (capitalized operating lease obligations x 6%)
|
|
77
|
|
|
90
|
|
|
n/a
|
|
Analysis of Financial Condition
Liquidity and Capital Resources
Our cash and cash equivalents balance was
$1,480 million
at
July 30, 2016
, compared with
$2,742 million
for the same period in
2015
. Our investment policy is designed to preserve principal and liquidity of our short-term investments. This policy allows investments in large money market funds or in highly rated direct short-term instruments that mature in 60 days or less. We also place certain dollar limits on our investments in individual funds or instruments.
Cash Flows
Operating cash flow provided by continuing operations was
$1,396 million
for the
six
months ended
July 30, 2016
compared with
$2,040 million
for the same period in
2015
. The decrease is primarily due to the payment of approximately $500 million of taxes during the first quarter of 2016 related to the Pharmacy Transaction. In April 2016, we issued $1.0 billion of unsecured debt that matures in 2026 and $1.0 billion of unsecured debt that matures in 2046. Combined with our prior year-end cash position, these proceeds allowed us to repurchase $1,389 million of debt at a market value of $1,800 million, fund current debt maturities, pay approximately $500 million in taxes related to the Pharmacy Transaction, invest in the business, pay dividends, and repurchase shares under our share repurchase program.
Share Repurchases
Under our current $10 billion share repurchase program, we have repurchased 125.0 million shares of common stock through
July 30, 2016
, at an average price of $70.57, for a total investment of $8.8 billion.
During the three and six months ended
July 30, 2016
, we repurchased 19.0 million and 30.4 million shares of our common stock, respectively, for a total investment of $1,350 million ($70.91 per share) and $2,243 million ($73.70 per share), respectively. During the three months ended August 1, 2015, we repurchased 8.2 million shares of our common stock for a total investment of $675 million ($81.94 per share), excluding the ASR initiated and prepaid in first quarter 2015 that settled in second quarter 2015. During the six months ended August 1, 2015, we repurchased 15.2 million shares of our common stock for a total investment of $1,240 million ($81.41 per share).
Dividends
We paid dividends totaling
$330 million
(
$0.56
per share) and
$666 million
(
$1.12
per share) for the
three and six
months ended
July 30, 2016
, respectively, and
$331 million
(
$0.52
per share) and
$665 million
(
$1.04
per share) for the
three and six
months ended
August 1, 2015
, a per share increase of
7.7
percent. We declared dividends totaling
$346 million
(
$0.60
per share) in
second
quarter
2016
, a per share increase of
7.1
percent over the
$356 million
(
$0.56
per share) of declared dividends during the
second
quarter of
2015
. We have paid dividends every quarter since our 1967 initial public offering, and it is our intent to continue to do so in the future.
Short-term and Long-term Financing
Our financing strategy is to ensure liquidity and access to capital markets, to manage our net exposure to floating interest rate volatility, and to maintain a balanced spectrum of debt maturities. Within these parameters, we seek to minimize our borrowing costs. Our ability to access the long-term debt and commercial paper markets has provided us with ample sources of liquidity. Our continued access to these markets depends on multiple factors including the condition of debt capital markets, our operating performance, and maintaining strong credit ratings. As of
July 30, 2016
our credit ratings were as follows:
|
|
|
|
|
Credit Ratings
|
Moody’s
|
Standard and Poor’s
|
Fitch
|
Long-term debt
|
A2
|
A
|
A-
|
Commercial paper
|
P-1
|
A-1
|
F2
|
If our credit ratings were lowered, our ability to access the debt markets and our cost of funds and other terms for new debt issuances could be adversely impacted. Each of the credit rating agencies reviews its rating periodically and there is no guarantee our current credit ratings will remain the same as described above.
We have additional liquidity through a committed $2.25 billion revolving credit facility that expires in October 2018. No balances were outstanding at any time during
2016
or
2015
.
Most of our long-term debt obligations contain covenants related to secured debt levels. In addition to a secured debt level covenant, our credit facility also contains a debt leverage covenant. We are, and expect to remain, in compliance with these covenants. Additionally, at
July 30, 2016
, no notes or debentures contained provisions requiring acceleration of payment upon a debt rating downgrade, except that certain outstanding notes allow the note holders to put the notes to us if within a matter of months of each other we experience both (i) a change in control; and (ii) our long-term debt ratings are either reduced and the resulting rating is noninvestment grade, or our long-term debt ratings are placed on watch for possible reduction and those ratings are subsequently reduced and the resulting rating is noninvestment grade.
We believe our sources of liquidity will continue to be adequate to maintain operations, finance anticipated expansion and strategic initiatives, fund debt maturities, pay dividends, and execute purchases under our share repurchase program for the foreseeable future. We continue to anticipate ample access to commercial paper and long-term financing.
Contractual Obligations and Commitments
As of the date of this report, other than the new borrowings and payments discussed in Note 5 of the Financial Statements, there were no material changes to our contractual obligations and commitments outside the ordinary course of business since January 30, 2016 as reported in our 2015 Form 10-K.
New Accounting Pronouncements
In February 2016, the FASB issued ASU No. 2016-02,
Leases
, to require organizations that lease assets to recognize the rights and obligations created by those leases on the balance sheet. The new standard is effective in 2019, with early adoption permitted. We are currently evaluating the effect the new standard will have on our financial statements.
We do not expect any other recently issued accounting pronouncements will have a material effect on our financial statements.
Forward-Looking Statements
This report contains forward-looking statements, which are based on our current assumptions and expectations. These statements are typically accompanied by the words “expect,” “may,” “could,” “believe,” “would,” “might,” “anticipates,” or words of similar import. The principal forward-looking statements in this report include: Our financial performance, statements regarding the adequacy of and costs associated with our sources of liquidity, the expected benefits of restructuring initiatives, the funding of debt maturities, the continued execution of our share repurchase program, our expected capital expenditures, the expected compliance with debt covenants, the expected impact of new accounting pronouncements, our intentions regarding future dividends, contributions and payments related to our pension plan, the expected return on plan assets, the expected outcome of, and adequacy of our reserves for, claims and litigation.
All such forward-looking statements are intended to enjoy the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended. Although we believe there is a reasonable basis for the forward-looking statements, our actual results could be materially different. The most important factors which could cause our actual results to differ from our forward-looking statements are set forth on our description of risk factors in Item 1A of our Form 10-K for the fiscal year ended
January 30, 2016
, which should be read in conjunction with the forward-looking statements in this report. Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update any forward-looking statement.